Tumor Immunology and Tumor Immunotherapy

  • HI-TRON Mainz
  • Immunology, Infection and Cancer
Portrait von Prof. Dr. Niels Halama, Leiter der Abteilung Tumorimmunologie und Tumorimmuntherapie

Prof. Dr. Niels Halama

Integration of broad aspects of immunological parameters for the successful development and optimization of therapeutic approaches in clinical translation.

Our Research

Tertiary lymphoid structures

Cancer immunology has moved from scientific insight into practice changing standards in oncology. Robust scientific evidence has provided the entry to successful clinical translation. The department Tumor Immunology and Tumor Immunotherapy is integrating broad aspects of immunological parameters (i.e. tissue-specific regulation, microbiome, metabolic regulation, genomic factors etc.) for the successful development and optimization of therapeutic approaches in clinical translation. An important part is to better understand the regulation of immune responses within tissues of solid tumors. Dedicated biomarker research for the identification of relevant immune cell phenotypes is also a decisive factor like understanding the cytokine regulatory network in specific disease situations. Deeper insights into the situation in human patients are provided by our fully-human preclinical Explant Model System, which is able to recapitulate the microenvironment of individual patients. In addition, new computational model systems, databases and machine learning (“artificial intelligence”) allow to further elaborate our understanding of the regulation of immune responses. Especially our explant model systems open new possibilities in development of new therapies. Newly developed therapies have been successfully translated into the clinic and combinatorial immunomodulation based on adaptive clinical trial protocols with biomarker driven selection programs are now being implemented.

Cancer immunotherapy has revolutionized oncology. As a standard of care for some cancer entities, broad application in the treatment of patients with hematologic and solid tumors has become a reality. Identification of patients for a specific immunomodulatory approach, identification of successful combinatorial immunotherapy (or combination with chemotherapy, radiation or other intervention) are all important next steps to be developed also together in the Helmholtz Institute for Translational Oncology (HITRON). Utilizing new model systems and informative trial designs, the connection of basic research and translational efforts make this area highly diverse and challenging, but show the potential for a future of personalized therapy in oncology.

Projects

Team

A 14-person team consisting of biologists, molecular biologists, physicists and physicians is working on the development and optimization of new therapeutic approaches to successfully combat cancer.

  • Portrait von Prof. Dr. Niels Halama, Leiter der Abteilung Tumorimmunologie und Tumorimmuntherapie

    Prof. Dr. Niels Halama

    Show profile
  • Employee image

    Dr. Azaz Ahmed

  • Portrait von Anna Berthel

    Dr. Anna Berthel

  • Employee image

    Dr. Silke Grauling-Halama

  • Portrait von Florian Heininger

    Florian Heininger

  • Portrait von Alicia Höflich

    Alicia Höflich

  • Portrait von Xu Holtkotte

    Dr. Xu Holtkotte

  • Portrait von Karla Kerekovic

    Karla Kerekovic

  • Employee image

    Alexandra Pöchmann

  • Portrait von Silke Will

    Silke Will

  • Employee image

    Jana Wolf

  • Employee image

    Xin-Wen Zhang

External employees

Ulrike Prüfer

Technical assistant

Send message

Selected publications

2023 - Cancers (Basel)
2016 - Cancer Cell

Get in touch with us

Portrait von Prof. Dr. Niels Halama, Leiter der Abteilung Tumorimmunologie und Tumorimmuntherapie

Prof. Dr. Niels Halama

Abteilungsleiter

Postal address:

Tumorimmunologie und Tumorimmuntherapie (D196) Deutsches Krebsforschungszentrum Obere Zahlbacher Str. 63 55131 Mainz
Portrait von Marion Drechsel

Marion Drechsel

Office Manager

Postal address:

Koordinierungsstelle HI-TRON Mainz (D190) Deutsches Krebsforschungszentrum Obere Zahlbacher Str. 63 55131 Mainz
Form

Form data is loaded ...